STOCK TITAN

Bioceres Crop Solutions (BIOX) Financials

BIOX NASDAQ
FY2026 annual
Revenue $238.3M -28.9% YoY
Net Income -$263.9M n/m YoY
EPS (Diluted) -$4.06 n/m YoY
Free Cash Flow $65.0M +46.8% YoY
Market Cap $12.8M as of Nov 18, 2026
Price / Sales 0.1x on $238.3M revenue, FY2026
Price / Earnings n/m net loss, so no earnings multiple, FY2026
Price / Book 1.2x on $10.7M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2026, ended Jun 30, 2026 Reported Currency USD FYE June

Newest figures come from the 20-F for FY2026, filed Oct 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIOX SEC filings page.

Bioceres Crop Solutions Corp. (BIOX) reported $238.3M in revenue for fiscal year 2026, down 28.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI BIOX FY2026

The latest figures show a shrinking operation that reports cash generation while losses and leverage weaken its financial cushion.

FY2026 generated operating cash flow of $66.0M despite a net loss of $263.9M, so reported cash and accounting earnings moved in opposite directions. Free cash flow of $65.0M alongside capital expenditures of $1.1M indicates the cash surplus was helped by sharply reduced reinvestment, not by profitable operations.

FY2026 revenue was $238M, down from $335M in FY2025; the contraction left less gross profit to support overhead. Gross margin fell 4.4 percentage points to 34.9%, while operating margin reached -9.8%, showing pressure passed through to operating results.

By FY2026, total equity had fallen to $10.7M while liabilities remained $414.2M, leaving a thin capital buffer. The 0.8x current ratio and 9.2x debt-to-equity ratio point to both near-term coverage pressure and high leverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 25 / 100
Financial Health Score 25/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bioceres Crop Solutions Corp.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
24

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Bioceres Crop Solutions Corp. scores 24/100 on it among other operating companies.

Growth
2

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Bioceres Crop Solutions Corp. scores 2/100 on it among other operating companies.

Leverage
6

Bioceres Crop Solutions Corp. carried $9.18 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2026, a debt-to-equity ratio of 9.18. With no EBITDA figure for fiscal year 2026, Bioceres Crop Solutions Corp. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 6/100 among other operating companies measured the same way.

Liquidity
12

Bioceres Crop Solutions Corp. held $0.80 of current assets for every $1 of current liabilities at the end of fiscal year 2026, a current ratio of 0.80. Liquidity ranks operating companies on that ratio, and Bioceres Crop Solutions Corp. scores 12/100 among other operating companies.

Cash Flow
85

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Bioceres Crop Solutions Corp. scores 85/100 on it among other operating companies.

Returns
19

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Bioceres Crop Solutions Corp. scores 19/100 on it among other operating companies.

Piotroski F-Score Weak
3/9

Bioceres Crop Solutions Corp. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality Mixed
N/A

Bioceres Crop Solutions Corp. reported a net loss of $263.9M while generating $66.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Bioceres Crop Solutions Corp. reported an operating loss of $23.4M against $39.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$238.3M
YoY-28.9%
5Y CAGR+2.6%
10Y CAGR+19.2%

Bioceres Crop Solutions Corp. generated $238.3M in revenue in fiscal year 2026. This represents a decrease of 28.9% from the prior year.

Net Income
-$263.9M
YoYn/m
5Y CAGRn/m
10Y CAGRn/m

Bioceres Crop Solutions Corp. reported a net loss of $263.9M in fiscal year 2026. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$4.06
YoYn/m
5Y CAGRn/m

Bioceres Crop Solutions Corp. earned -$4.06 per diluted share (EPS) in fiscal year 2026. The change from the prior year is not meaningful, because that figure was zero or negative.

EBITDA

Not reported for fiscal year 2026.

Cash & Balance Sheet

Free Cash Flow
$65.0M
YoY+46.8%
5Y CAGRn/m
10Y CAGRn/m

Bioceres Crop Solutions Corp. generated $65.0M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 46.8% from the prior year.

Cash & Debt
$11.2M
YoY-65.6%
5Y CAGR-20.8%

Bioceres Crop Solutions Corp. held $11.2M in cash against $98.3M in long-term debt as of fiscal year 2026.

Shares Outstanding
64M
YoY+0.9%
5Y CAGR+9.2%

Bioceres Crop Solutions Corp. had 64M shares outstanding in fiscal year 2026. This represents an increase of 0.9% from the prior year.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Gross Margin
34.9%
YoY-4.4pp
5Y change-8.5pp
10Y change+9.2pp

Bioceres Crop Solutions Corp.'s gross margin was 34.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 4.4 percentage points from the prior year.

Operating Margin
-9.8%
YoY-9.2pp
5Y change-28.1pp
10Y change-10.3pp

Bioceres Crop Solutions Corp.'s operating margin was -9.8% in fiscal year 2026, reflecting core business profitability. This is down 9.2 percentage points from the prior year.

Return on Equity
-2462.9%
YoY-2442.0pp
5Y change-2452.8pp
10Y change-2455.9pp

Bioceres Crop Solutions Corp.'s ROE was -2462.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 2442.0 percentage points from the prior year.

Net Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$11.0M
YoY-26.0%
5Y CAGR+14.5%
10Y CAGR+29.2%

Bioceres Crop Solutions Corp. invested $11.0M in research and development in fiscal year 2026. This represents a decrease of 26.0% from the prior year.

Capital Expenditures
$1.1M
YoY-81.3%
5Y CAGR-17.8%
10Y CAGR+5.7%

Bioceres Crop Solutions Corp. invested $1.1M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 81.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2026.

BIOX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIOX annual income statement
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1620-F
Revenue$238.3M-28.9%$335.1M-27.9%$464.8M+10.6%$420.1M+25.4%$334.8M+59.8%$209.5M+21.0%$173.1M+7.8%$160.6M+20.3%$133.5M$41.2M
Cost of Revenue$155.1M-23.8%$203.4M-26.9%$278.2M+18.2%$235.5M+13.0%$208.4M+75.6%$118.6M+26.8%$93.6M+7.6%$87.0M+12.8%$77.1M$30.6M
Gross Profit$83.2M-36.8%$131.7M-29.4%$186.6M+1.1%$184.6M+46.0%$126.5M+39.2%$90.9M+14.3%$79.5M+8.0%$73.6M+30.5%$56.4M$10.6M
R&D Expenses$11.0M-26.0%$14.9M-13.2%$17.2M+12.0%$15.3M+120.9%$6.9M+23.7%$5.6M+33.9%$4.2M+13.7%$3.7M-6.6%$4.0M$854K
Operating Income-$23.4Mn/m-$2.2M-104.9%$45.9M-15.4%$54.2M+35.9%$39.9M+3.9%$38.4M-1.9%$39.1M+22.0%$32.1M+104.2%$15.7M$207K
Interest Expense$39.9M+38.4%$28.8M+7.3%$26.9M+13.0%$23.8M+32.7%$17.9M-15.6%$21.2M+1.7%$20.9M-10.8%$23.4M+36.2%$17.2M$7.2M
Income Tax$7.0M+446.3%$1.3M-66.3%$3.8Mn/m-$1.1M-105.9%$18.0M+25.2%$14.4M+550.3%$2.2M-68.4%$7.0Mn/m-$10.9M-$1.9M
Net Income-$263.9Mn/m-$55.4M-1396.1%$4.3M-77.2%$18.8Mn/m-$7.2Mn/m-$6.9M-304.5%$3.4Mn/m-$18.4Mn/m-$11.0M-$5.9M
EPS (Basic)-$4.06n/m-$0.88-1388.8%$0.07-77.5%$0.30n/m-$0.17n/m-$0.18-288.4%$0.09n/m-$0.60n/m-$0.39-$0.21
EPS (Diluted)-$4.06n/m-$0.88-1402.2%$0.07-77.4%$0.30n/m-$0.17n/m-$0.18-290.0%$0.09n/m-$0.60n/m-$0.39N/A
Diluted Shares (Avg)64M+0.7%63M-0.4%63M+0.5%63M+49.4%42M+7.9%39M+7.7%36M+19.5%30M+8.5%28MN/A

Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.

No annual filing on record for: FY2017.

BIOX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIOX annual balance sheet
MetricFY2620-FFY256-KFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1620-F
Total Assets$448.2M-41.3%$763.6M-10.4%$852.5M+4.2%$818.1M+57.9%$518.2M+31.3%$394.6M+32.6%$297.6M+22.7%$242.5M+23.3%$196.6MN/A
Current Assets$215.4M-30.1%$308.3M-24.6%$408.7M+2.9%$397.1M+33.4%$297.7M+40.8%$211.5M+28.4%$164.7M+67.7%$98.2M+15.1%$85.3MN/A
Cash & Equivalents$11.2M-65.6%$32.7M-26.5%$44.5M-7.6%$48.1M+43.8%$33.5M-7.1%$36.0M-15.2%$42.5M+1132.2%$3.5M+55.8%$2.2MN/A
Inventory$46.4M-47.0%$87.6M-30.4%$125.9M-10.3%$140.4M+11.4%$126.0M+106.5%$61.0M+108.0%$29.3M+7.4%$27.3M+41.1%$19.4MN/A
Accounts ReceivableN/A$165.9M-20.0%$207.3M+31.2%$158.0M+41.4%$111.8M+25.9%$88.8M+20.7%$73.5M+24.2%$59.2M+12.0%$52.9MN/A
Goodwill$28.6M-74.5%$112.2M0.0%$112.2M0.0%$112.2M+210.9%$36.1M+25.5%$28.8M+12.6%$25.5M-14.4%$29.8M+106.4%$14.4MN/A
Total Liabilities$414.2M-11.6%$468.4M-6.5%$501.2M+2.8%$487.6M+35.5%$359.9M+18.3%$304.3M+28.5%$236.8M+31.3%$180.4M+10.3%$163.5MN/A
Current Liabilities$270.3M-20.0%$338.0M+2.6%$329.3M+10.2%$298.7M+34.2%$222.7M+32.5%$168.0M+28.7%$130.6M+12.2%$116.5M-1.9%$118.7MN/A
Non-Current Liabilities$143.8M+10.3%$130.4M-24.1%$171.9M-9.0%$188.9M+37.6%$137.3M+0.7%$136.3M+28.3%$106.2M+66.2%$63.9M+42.6%$44.8MN/A
Long-Term Debt$98.3M+53.3%$64.1M-4.5%$67.2M-39.3%$110.7M-18.3%$135.4M+57.8%$85.8M+44.0%$59.6M+32.1%$45.1M+75.4%$25.7MN/A
Total Equity$10.7M-96.0%$265.4M-15.7%$315.0M+5.5%$298.6M+134.5%$127.4M+88.0%$67.7M+46.7%$46.2M-2.4%$47.3M+244.9%$13.7M$83.7M

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Retained Earnings.

No annual filing on record for: FY2017.

BIOX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIOX annual cash flow statement
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1620-F
Operating Cash Flow$66.0M+32.3%$49.9M+19.6%$41.7M+1511.4%$2.6Mn/m-$17.5Mn/m-$6.2M-166.6%$9.3M-68.6%$29.7M+61.5%$18.4M-$1.2M
Capital Expenditures$1.1M-81.3%$5.6M-42.4%$9.8M-13.8%$11.4M+228.5%$3.5M+23.3%$2.8M+70.4%$1.6M-19.4%$2.0M-26.8%$2.8M$608K
Free Cash Flow$65.0M+46.8%$44.3M+38.6%$31.9Mn/m-$8.8Mn/m-$21.0Mn/m-$9.0M-217.5%$7.7M-72.3%$27.7M+77.3%$15.6M-$1.8M
Investing Cash Flow-$5.9Mn/m-$6.1Mn/m-$28.7Mn/m-$25.7M-986.2%$2.9Mn/m-$8.3Mn/m-$7.8Mn/m-$3.3Mn/m-$8.2M-$41.9M
Financing Cash Flow-$78.7Mn/m-$50.7Mn/m-$10.1M-130.5%$33.0M+122.3%$14.8M+101.5%$7.4M-78.1%$33.5Mn/m-$26.9Mn/m-$10.5M$44.0M
Dividends PaidN/A$72K-58.8%$175K-61.3%$452KN/AN/AN/AN/AN/A$14K

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Share Buybacks.

No annual filing on record for: FY2017.

BIOX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIOX annual financial ratios
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1620-F
Gross Margin34.9%-4.4pp39.3%-0.8pp40.1%-3.8pp44.0%+6.2pp37.8%-5.6pp43.4%-2.6pp45.9%+0.1pp45.9%+3.6pp42.3%25.7%
Operating Margin-9.8%-9.2pp-0.7%-10.5pp9.9%-3.0pp12.9%+1.0pp11.9%-6.4pp18.3%-4.3pp22.6%+2.6pp20.0%+8.2pp11.8%0.5%
Net Margin-110.8%-16.5%-17.5pp0.9%-3.5pp4.5%+6.6pp-2.1%+1.1pp-3.3%-5.2pp1.9%+13.4pp-11.4%-3.2pp-8.3%-14.2%
Return on Equity-2462.9%-2442.0pp-20.9%-22.2pp1.4%-4.9pp6.3%+11.9pp-5.7%+4.5pp-10.1%-17.4pp7.3%+46.1pp-38.8%+41.7pp-80.5%-7.0%
Return on Assets-58.9%-51.6pp-7.3%-7.8pp0.5%-1.8pp2.3%+3.7pp-1.4%+0.3pp-1.7%-2.9pp1.1%+8.7pp-7.6%-2.0pp-5.6%N/A
Current Ratio0.80-0.1x0.91-0.3x1.24-0.1x1.330.0x1.34+0.1x1.260.0x1.26+0.4x0.84+0.1x0.72N/A
Debt-to-Equity9.18+8.9x0.240.0x0.21-0.2x0.37-0.7x1.06-0.2x1.270.0x1.29+0.3x0.95-0.9x1.87N/A
Liabilities-to-Equity38.65+36.9x1.76+0.2x1.590.0x1.63-1.2x2.83-1.7x4.49-0.6x5.13+1.3x3.81-8.1x11.92N/A
Asset Turnover0.53+0.1x0.44-0.1x0.550.0x0.51-0.1x0.65+0.1x0.53-0.1x0.58-0.1x0.660.0x0.68N/A
FCF Margin27.3%+14.1pp13.2%+6.3pp6.9%+9.0pp-2.1%+4.2pp-6.3%-2.0pp-4.3%-8.7pp4.4%-12.8pp17.2%+5.5pp11.7%-4.5%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

No annual filing on record for: FY2017.

Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Bioceres Crop Solutions Corp. BIOX FY2026 $238.3M -$263.9M N/A $12.8M 25/100
Origin Agritech Limited SEED FY2025 $12.8M -$7.5M -58.4% $9.5M 14/100
American Vanguard Corporation AVD FY2025 $515.1M -$49.9M -9.7% $22.4M 26/100
Nexentis Technologies Inc. NXTS FY2025 N/A -$4.0M N/A $831K —
FMC Corporation FMC FY2025 $3.5B -$2.2B -64.6% $728.0M 21/100
Intrepid Potash, Inc IPI FY2025 $298.3M $11.2M 3.8% $400.4M 52/100

Frequently Asked Questions

Bioceres Crop Solutions Corp. (BIOX) reported $238.3M in total revenue for fiscal year 2026. This represents a -28.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Bioceres Crop Solutions Corp. (BIOX) revenue declined by 28.9% year-over-year, from $335.1M to $238.3M in fiscal year 2026.

No, Bioceres Crop Solutions Corp. (BIOX) reported a net loss of $263.9M in fiscal year 2026.

Bioceres Crop Solutions Corp. (BIOX) reported diluted earnings per share of -$4.06 for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2026, Bioceres Crop Solutions Corp. (BIOX) had $11.2M in cash and equivalents against $98.3M in long-term debt.

Bioceres Crop Solutions Corp. (BIOX) had a gross margin of 34.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

Bioceres Crop Solutions Corp. (BIOX) had an operating margin of -9.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

Bioceres Crop Solutions Corp. (BIOX) has a return on equity of -2462.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

Bioceres Crop Solutions Corp. (BIOX) generated $65.0M in free cash flow during fiscal year 2026. This represents a 46.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Bioceres Crop Solutions Corp. (BIOX) generated $66.0M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

Bioceres Crop Solutions Corp. (BIOX) had $448.2M in total assets as of fiscal year 2026, including both current and long-term assets.

Bioceres Crop Solutions Corp. (BIOX) invested $1.1M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

Bioceres Crop Solutions Corp. (BIOX) invested $11.0M in research and development during fiscal year 2026.

Bioceres Crop Solutions Corp. (BIOX) had 64M shares outstanding as of fiscal year 2026.

Bioceres Crop Solutions Corp. (BIOX) had a current ratio of 0.80 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

Bioceres Crop Solutions Corp. (BIOX) had a debt-to-equity ratio of 9.18 as of fiscal year 2026. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Bioceres Crop Solutions Corp. (BIOX) had a liabilities-to-equity ratio of 38.65 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Bioceres Crop Solutions Corp. (BIOX) had a return on assets of -58.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

Bioceres Crop Solutions Corp. (BIOX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $12.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Bioceres Crop Solutions Corp. (BIOX) trades at 0.1x sales, its market capitalization divided by $238.3M revenue, FY2026. The market capitalization is $12.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Bioceres Crop Solutions Corp. (BIOX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Bioceres Crop Solutions Corp. (BIOX) reported a net loss of $263.9M while generating $66.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Bioceres Crop Solutions Corp. (BIOX) reported an operating loss of $23.4M against $39.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Bioceres Crop Solutions Corp. (BIOX) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top